Dysphagia is associated with presynaptic dopaminergic dysfunction and greater non-motor symptom burden in early drug-naïve Parkinson’s patients by Polychronis, Sotirios et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1371/journal.pone.0214352
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Polychronis, S., Dervenoulas, G., Yousaf, T., Niccolini, F., Pagano, G., & Politis, M. (2019). Dysphagia is
associated with presynaptic dopaminergic dysfunction and greater non-motor symptom burden in early drug-
naïve Parkinson’s patients. PLoS ONE, 14(7), [e0214352]. https://doi.org/10.1371/journal.pone.0214352
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 12. Sep. 2019
RESEARCH ARTICLE
Dysphagia is associated with presynaptic
dopaminergic dysfunction and greater non-
motor symptom burden in early drug-naïve
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Abstract
Background
The underlying pathophysiology of dysphagia is multifactorial and evidence clarifying the
precise mechanisms are scarce. Dysfunction in dopamine-related and non-dopamine-
related pathways, changes in cortical networks related with swallowing and peripheral
mechanisms have been implicated in the pathogenesis of dysphagia. We aimed at investi-
gating whether dysphagia is associated with presynaptic dopaminergic deficits, faster motor
symptom progression and cognitive decline in a population of early drug-naïve patients with
Parkinson’s disease.
Methods
By exploring the database of Parkinson’s Progression Markers Initiative we identified forty-
nine early drug-naïve Parkinson’s disease patients with dysphagia. Dysphagia was identi-
fied with SCOPA-AUT question 1 (answer regularly) and was assessed with MDS-UPDRS
Part-II, Item 2.3 (Chewing and Swallowing). We compared Parkinson’s disease patients
with dysphagia to Parkinson’s disease patients without dysphagia, and investigated differ-
ences in striatal [123I]FP-CIT single photon emission computed tomography levels. Using
Cox proportional hazards analyses, we also evaluated whether dysphagia can predict motor
deterioration and cognitive dysfunction.
Results
Parkinson’s disease patients with dysphagia, harbored a greater deterioration regarding
motor and non-motor symptoms and decreased [123I]FP-CIT binding when compared with
patients without dysphagia. Higher burden of dysphagia (MDS-UPDRS-II, item 2.3) was cor-
related with lower [123I]FP-CIT uptakes within the striatum (rs = −0.157; P = 0.002) and the
caudate (rs = −0.156; P = 0.002). The presence of dysphagia was not a predictor of motor
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progression (Hazard ratio [HR]: 1.143, 95% confidence interval [CI]: 0.848–1.541; P =
0.379) or cognitive decline (HR: 1.294, 95% CI: 0.616–2.719; P = 0.496).
Conclusions
Dysphagia is associated with decreased presynaptic dopaminergic integrity within caudate
and greater motor and non-motor symptoms burden in early drug-naïve PD.
Introduction
Swallowing and chewing difficulties, defined as dysphagia on ICD-10, are characterised by the
inability to safely swallow fluids and /or solid food and are accounting for severe complica-
tions, commonly aspiration pneumonia that substantially increases mortality rates. Dysphagia
is more likely to have a neurologic basis and are an important issue in Parkinson’s disease
(PD) [1]. Between 70 to 100% of patients with PD have dysphagia throughout the disease pro-
gression. The prevalence increases proportionally in later stages of the disease [2–4]. Aspira-
tion pneumonia in the context of dysphagia is regarded one of the most important factors
contributing to decreased life expectancy of PD patients [5]. In addition, malnutrition, dehy-
dration and medication intake complications are further consequences of dysphagia that con-
tribute to significant decline in the quality of patients life [6]. The pathophysiology underlying
dysphagia in PD remains elusive. Several cortical, subcortical and peripheral mechanisms have
been partially implicated without a robust and conclusive justification. The swallowing process
involves multiple cortical areas, including primary sensorimotor cortex, sensorimotor integra-
tion areas, insula, anterior cingulate cortex and the supplementary motor cortex [7–10]. Dys-
phagia can also be attributed to brainstem pathology. Notably, early in the course of PD, areas
that generate the central swallowing pathway in the medulla (motor nucleus of glossopharyn-
geal nerve, vagus nerve, reticular activating system) are exposed to the neurodegenerative pro-
cesses [11, 12]. In addition, the pedunculopontine tegmental nucleus, receives abnormal
inhibitory through the pallidum and is thus further exposed to neurodegeneration [13].
In this study we investigated the association of dysphagia and dopaminergic deficits using
[123I]FP-CIT single photon emission computed tomography (SPECT). Finally, we explore
whether dysphagia was a predictor of motor symptom progression and cognitive decline.
Methods
Subjects and clinical evaluation
From the 412 PD patients included in the Parkinson’s Progression Markers Initiative (PPMI)
database (www.ppmi-info.org/data), a total of 398 early drug-naïve PD patients underwent
both [123I]FP-CIT SPECT assessments, and therefore were integrated in our analytical
approach. Among these 398 PD patients, we identified 307 cognitively intact (MoCA�26),
with a complete 60-month follow-up and we included them for the longitudinal analysis. All
PD patients were recruited between 2010–2015, diagnosed with PD less than two years prior
to a screening visit, never treated with dopamine replacement therapy and presented with two
among bradykinesia, resting tremor and rigidity or with asymmetric resting tremor/bradyki-
nesia at screening. The diagnosis was confirmed by the presence of dopaminergic deficit at
[123I]FP-CIT SPECT imaging.
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The presence of dysphagia was identified with the SCOPA-AUT question 1 (In the past
month, have you had difficulty swallowing or have you choked? Answer: regularly) and quan-
tified according to the Movement Disorder Society-sponsored revision of the Unified Parkin-
son’s Disease Rating Scale (MDS-UPDRS) Part-II, Item 2.3 (Chewing and Swallowing)� 1.
This item is a clinician-based scale consisting of 5 scores, rating between 0 (normal) and 4
(most severe impairment).
Motor symptom burden was measured with the MDS-UPDRS-III and staged with the
Hoehn and Yahr (H&Y) scale. Each motor domain (bradykinesia, resting tremor, rigidity, pos-
tural instability) was calculated using specific MDS-UPDRS-III sub-items as follows: bradyki-
nesia (Total score range 0–52) = sum of Item 3.4 finger tapping, item 3.5 hand movements,
item 3.6 pronation-supination movements of hands, item 3.7 toe tapping, item 3.8 leg agility,
item 3.9 arising from chair, item 3.13 posture and item 3.14 body bradykinesia; rigidity (Total
score range 0–20) = sum of Item 3.3 rigidity (neck, upper limbs and lower limbs); resting
tremor (total score range 0–24) = sum of item 3.17 rest tremor amplitude (lip/jaw, upper limbs
and lower limbs) and item 3.18 constancy of tremor; axial (total score range 0–12) = sum of
item 3.10 gait, item 3.11 freezing of gait and item 3.12 postural stability (PPMI, 2011). MDS-
UPDRS-II score was calculated excluding Item 2.3 (Chewing and Swallowing).
PD motor phenotypes were identified as either tremor-dominant or akinetic-rigid by apply-
ing a numerical ratio derived from the mean score of tremor and the mean score of rigidity-
akinesia [14]. Patients with ratio < 0.8 were classified as akinetic-rigidity phenotype, patients
with ratio> 1.0 were classified as tremor-dominant phenotype and patients with ratio between
0.8 and 1 were classified as mixed subtype. Non-motor symptoms were assessed using MDS-
UPDRS-I and the Scale for Outcomes for PD–Autonomic function (SCOPA-AUT). Neuropsy-
chiatric symptoms were assessed with the short version of the 15-item Geriatric Depression
Scale (GDS) and the State Trait Anxiety Total scale (STAI). Sleep disorders were assessed with
the Epworth Sleeping Scale and REM sleep behavior disorder questionnaire (RBDQ). Cogni-
tive impairment was assessed with the Montreal cognitive assessment (MoCA). Olfactory dys-
function was assessed with the University of Pennsylvania Smell Identification Test (UPSIT).
Disability was estimated using the Modified Schwab & England Activity of Daily Living
(ADL). An annual assessment of cognition included scales exploring four major cognitive
domains including memory [Hopkins Verbal Learning Test-Revised (HVLT-R) Recall,
HVLT-R Recognition Discrimination], visuospatial functions [Judgment of Line Orientation
(Benton)], working memory and executive functions [Letter Number Sequencing (LNS),
Semantic Fluency], attention and processing speed [Symbol Digit Modalities Test (SDMT)].
Dopaminergic imaging
SPECT images were obtained 4±0.5 hours after administrating an injection of approximately
185 MBq [123I]FP-CIT. [123I]FP-CIT SPECT scans were analysed following the imaging tech-
nical operations manual (http://ppmi-info.org/). Raw SPECT data was acquired into a 128 x
128 matrix stepping each 3 degrees for a total of 120 (or 4 degrees for a total of 90) projections
in a window centred on 159±10%KeV. The total scan duration was 30–45 minutes. A Chang 0
attenuation correction was applied using a customised Mu determined empirically from the
anthropomorphic brain phantom acquired at each site. A standard Gaussian 3D 6.0mm filter
was applied to each image volume and then normalised to standard Montreal Neurologic
Institute space. Each scan was interpreted by two independent readers who were blinded to
the subjects’ demographics and characteristics. For quantification, SPECT image volumes
were spatially normalized to an Ioflupane template. The eight most prominent axial slices con-
taining striatum were summed and then a standardized volume of interest (VOI) template was
Dysphagia and presynaptic dopaminergic dysfunction in early drug-naïve Parkinson’s patients
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applied to this image. VOI analyses were performed on the left and right caudate and putamen
with the occipital region serving as a reference tissue. Specific binding ratios (SBR) were calcu-
lated as the ratio of the caudate or putamen VOI count density divided by count density of the
occipital cortex minus 1. This measure approximates the binding potential, BPND, when the
tracer is in equilibrium at the target site and was previously reported with Ioflupane SPECT
[15].
Assessment of motor progression and cognitive decline
Motor progression was defined as a change of one point in the H&Y scale at the follow-up vis-
its. Cognitive decline was defined as having a clinical deterioration of cognitive function
reported by the patient or the caregiver, a MoCA score<26 and at least 2 test scores (of six
neuropsychological tests indicated above; regardless of the domain tested). Scores should be
above 1.5 standard deviation and below the standardized mean scores of education and age.
Norms were applied according to current literature [15]. Follow-up visits took place in the out-
patient unit of the reference hospitals once every 6 months and 307 early drug-naïve PD
patients were followed up for an average of 60 months.
Standard protocol approvals, registrations, and patient consents
This study is registered with ClinicalTrials.gov (No: NCT01141023). Each PPMI site has
received approval from an ethical committee on human experimentation before the study’s
initiation. The present study was an analysis of anonymized data and institutional review
board (IRB) approval was obtained at King’s College London. All data were obtained with
informed written consent in accordance with established human subject research procedures
expressed in the Declaration of Helsinki. Our study was performed in full accordance with the
local IRB guidelines and according to the STROBE guidelines [16].
Statistical analysis
Statistical analysis and graph illustration were performed with SPSS (version 20) and Graph-
Pad Prism (version 6.0c) for MAC OS X, respectively. For all variables, variance homogeneity
and Gaussianity were tested with Kolmogorov-Smirnov test.
Multivariate analysis of variance (MANOVA) was used to assess the main differences in
clinical, imaging and non-imaging parameters between PD patients with and without dyspha-
gia. If the overall multivariate test was significant, P-values for each variable were calculated
following Bonferroni’s multiple comparisons test. Categorical variables are expressed as pro-
portions and compared using the χ2 test. We interrogated correlations between the swallowing
and chewing scores at the MDS-UPDRS-II item 2.3 and imaging data using Spearman’s rank
correlation. To explore whether dysphagia can predict motor disease burden and cognitive
dysfunction, Cox proportional hazards analyses were carried out. The time to occurrence of
the first event for a given subject was used in the Cox model. All data are presented as
mean ± standard deviation (SD), and the level α was set for all comparisons at P<0.05,
corrected.
Results
Clinical characteristics
The prevalence of dysphagia in the cohort of early drug-naïve PD patients was 12.3% (49/398).
No significant differences were observed for demographic characteristics (age: P>0.1, gender:
P>0.1, disease duration: P>0.1 and family history of PD: P>0.1) between the two groups.
Dysphagia and presynaptic dopaminergic dysfunction in early drug-naïve Parkinson’s patients
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Dysphagia was more common in early drug-naïve PD patients with akinetic-rigid motor
phenotype (34/49; 69.4% vs 207/349; 59.3%). However, no significant difference was observed
in H&Y stage (P>0.1), MDS-UPDRS-III (P>0.1), bradykinesia (P>0.1), rigidity (P>0.1),
axial (P>0.1) and resting tremor (P>0.1) subscores between early drug-naïve PD patients
with and without dysphagia (Table 1). Early drug-naïve PD patients with dysphagia had signif-
icant higher burden in motor aspects of daily living as measured by the MDS-UPDRS-II
(P<0.001).
Early drug-naïve PD patients with dysphagia had greater non-motor symptoms burden
compared to those without dysphagia. In specific, early drug-naïve PD patients with dysphagia
had higher MDS-UPDRS-I scores (P<0.001), worse autonomic dysfunction symptoms (SCO-
PA-AUT; P<0.001), depressive symptoms (GDS; P<0.001), excessive daytime sleepiness (ESS;
P<0.001) and RBD (RBDQ; P = 0.016) compared to PD patients without dysphagia (Table 1).
No significant differences were found in anxiety (STAI; P>0.1), cognitive function (MoCA;
P>0.1), olfactory dysfunction (UPSIT; P>0.1) and disability scores (ADL; P = 0.336) between
early drug-naïve PD patients with and without speech and chewing difficulties.
Table 1. Demographic and clinical characteristics of early drug-naïve PD patients.
PD with dysphagia
(n = 49)
PD without dysphagia
(n = 349)
P value�
DEMOGRAPHIC CHARACTERISTICS
Age (mean±SD) 62.76 (±8.04) 61.46 (±9.92) P>0.1
Gender male, % (n) 61.2% (30) 65.9% (230) P>0.1
Disease duration (months; mean±SD) 6.96 (±6.21) 6.41 (±6.42) P>0.1
Family history of PD, % (n) 32.7% (16) 24.1% (84) P>0.1
Motor Subtypes, % (n) AR: 69.4% (34)
TD: 22.4% (11)
Mixed: 8.2% (4)
AR: 59.3% (207)
TD: 30.1% (105)
Mixed: 10.6% (37)
P<0.05
Hoehn and Yahr scale (mean±SD) 1.59 (±0.49) 1.56 (±0.5) P>0.1
MDS-UPDRS-II (No Swallowing) (mean±SD) 9.14 (±4.98) 4.9 (±3.67) <0.001
MDS-UPDRS-III (mean±SD) 20.65 (±8.12) 20.20 (±8.66) P>0.1
Bradykinesia subscore (mean±SD) 10.69 (±4.91) 10.03 (±5.55) P>0.1
Rigidity subscore (mean±SD) 3.59 (±2.76) 3.79 (±2.6) P>0.1
Axial subscore (mean±SD) 1.02 (±1.09) 0.81 (±0.939) P>0.1
Resting Tremor subscore (mean±SD) 3.82 (±3.1) 4.47 (±3.1) P>0.1
MDS-UPDRS-I (mean± SD) 2.06 (±2.39) 1.11 (±1.39) <0.001
SCOPA-AUT (mean±SD) 14.94 (±7.28) 8.84 (±5.71) <0.001
GDS (mean±SD) 3.8 (±3.31) 2.11 (±2.16) <0.001
STAI (mean±SD) 92.47 (±6.96) 93.40 (±8.33) P>0.1
ESS (mean±SD) 7.43 (±3.2) 5.58 (±3.42) <0.001
RBDQ Score (mean±SD) 5.2 (±3.06) 3.96 (±2.56) 0.016
MoCA (mean±SD) 27.43 (±1.82) 27.08 (±2.38) P>0.1
UPSIT (mean±SD) 21.06 (±9.3) 22.64 (±8.07) P>0.1
FUNCTIONAL ASSESSMENT
ADL (mean±SD) 92.45 (±6.7) 93.32 (±5.79) P>0.1
ADL: Modified Schwab & England Activity of Daily Living; AR: Akinetic-rigid dominant; ESS: Epworth Sleeping Scale; GDS: 15-item Geriatric Depression Scale;
MoCA: Montreal Cognitive Assessment Scale; RBDQ: REM sleep behaviour disorder questionnaire; SCOPA-AUT: the scale for outcomes for PD-autonomic function;
STAI: state and train anxiety scale; TD: Tremor dominant; UPSIT: University of Pennsylvania Smell Identification Test.
�P values are Bonferroni corrected.
https://doi.org/10.1371/journal.pone.0214352.t001
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Imaging assessment: Presynaptic dopaminergic function
Early drug-naïve PD patients with dysphagia had significant lower [123I]FP-CIT uptakes in the
striatum (P = 0.016) compared to those without dysphagia (Figs 1 and 2; Table 2). Within the
striatum [123I]FP-CIT uptakes was significantly decreased in the caudate (P = 0.008) but not
putamen (P>0.1) of early drug-naïve PD patients with dysphagia. Worse swallowing and
chewing scores at the MDS-UPDRS-II item 2.3 were associated with lower [123I]FP-CIT
uptakes in the striatum (rho = −0.157; P = 0.002) and caudate (rho = −0.156; P = 0.002: Fig 2).
Motor progression and cognitive decline
Over a period of three years, 180/355 (50.7%) drug-naïve PD patients showed motor progres-
sion and 51/307 (16.6%) of them developed cognitive impairment. Cox proportional hazards
analysis showed that the presence of dysphagia in early drug-naïve PD patients has no
influence on cognitive decline at the follow-up (Hazard Ratio (HR): 1.735, 95% Confidence
Interval (CI): 0.890–3.381; P = 0.106) or motor progression (HR: 1.259, 95% CI: 0.830–1.907;
P = 0.278).
Discussion
Our findings indicate that early drug-naïve PD patients with dysphagia have greater presynap-
tic dopaminergic dysfunction in the caudate and non-motor symptoms burden. Moreover, the
Fig 1. [123I]FP-CIT SPECT images in Parkinson’s disease patients with and without dysphagia. (A) 63-year-old healthy control showing typical
[123I]FP-CIT specific binding ratios in the caudate (SBR: 3.87) and putamen (SBR: 2.65) (B) 63-year-old male without swallowing difficulties exhibiting
slight dopaminergic deficits as reflected by [123I]FP-CIT specific binding ratios in the caudate (SBR: 2.92) and putamen (SBR: 2.15); (C) 63-year-old
female with swallowing difficulties demonstrating larger striatal dopaminergic deficits as reflected by [123I]FP-CIT specific binding ratios in the caudate
(SBR: 1.00) and putamen (SBR: 0.58).
https://doi.org/10.1371/journal.pone.0214352.g001
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loss of striatal dopaminergic function is correlated with dysphagia in early drug-naïve PD
patients. Finally, dysphagia is not associated with motor progression or an increased risk of
cognitive dysfunction at the follow-up in early drug-naïve PD patients.
The prevalence of dysphagia in the general PD patients’ population ranges between 9 to
77% [17]. We found that dysphagia occur in 12.3% (49/398) of early drug-naïve PD patients
Fig 2. Presynaptic dopaminergic deficit in the group of early drug-naïve PD patients with and without dysphagia. Box-plot showing decreased
[123I]FP-CIT uptakes in the (A) striatum and (B) caudate of early drug-naïve PD patients with swallowing difficulties. Correlations between the
degree of swallowing impairment (MDS-UPDRS-II, item 2.3) and [123I]FP-CIT uptake in the (C) striatum (rho = −0.157; P = 0.002) and (D) caudate
(rho = −0.156; P = 0.002) of early drug-naïve PD patients. SD = Swallowing difficulties.
https://doi.org/10.1371/journal.pone.0214352.g002
Table 2. [123I]FP-CIT uptakes in Striatum for the groups of early drug-naïve PD patients with and without
dysphagia.
Regions of Interest PD with dysphagia (n = 49) PD without dysphagia (n = 349) P value�
Striatum (mean±SD) 1.28 (±0.48) 1.43 (±0.38) 0.016
Caudate (mean±SD) 1.79 (±0.66) 2.03 (±0.53) 0.008
Putamen (mean±SD) 0.78 (±0.37) 0.83 (±0.28) P>0.1
�P values are Bonferroni corrected.
https://doi.org/10.1371/journal.pone.0214352.t002
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and are more frequent in akinetic-rigid phenotype. This is one of few studies to report the
prevalence of dysphagia in early drug-naïve patients with PD [18, 19].
Early drug-naïve PD patients with dysphagia had increased non-motor symptom burden
suggesting a close association between dysphagia and PD non-motor features. Among the
non-motor symptoms, early drug-naïve PD patients with dysphagia showed worse autonomic
dysfunction, depressive symptoms, excessive daytime sleepiness and disordered REM sleeping
behaviour. On the contrary, anxiety, cognition, olfactory dysfunction and disability did not
differ between the two groups. The fact that olfactory dysfunction did not differ between the
two groups may suggest that, in our population, the lack of smell identification was not impair-
ing the food recognition and the quality of chewing (oral phase of swallowing) and swallowing
(pharyngeal phase). A recent study has underlined that patients with dysphagia is prone to
affective symptomatology such as depression and fear. [18, 19].
A recent study suggested that cognitive impairment (frontal/executive and learning/mem-
ory) is frequently corelated with the oral phase of swallowing in early PD patients [18, 19].
However, we did not find any alterations in cognitive functions among early drug-naïve PD
patients with and without dysphagia. Moreover, the presence of dysphagia at baseline did not
increase the possibilities of harbouring cognitive decline at the follow-up visits.
Furthermore, early drug-naïve patients with PD and dysphagia had substantially decreased
striatal [123I]FP-CIT levels when compared to patients without dysphagia. The decrease of
striatal presynaptic dopaminergic function was associated with the degree of dysphagia. To the
best of our knowledge, this is the first time which striatal presynaptic dopamine deficits were
associated with the degree of dysphagia in PD. We found that early drug-naïve PD patients
with dysphagia had the greater loss of dopaminergic nigrostriatal terminals in striatum and
specifically in caudate. Loss of dopaminergic nigrostriatal terminals in the caudate nucleus is a
general marker of PD severity, but could be also associated with the pathophysiology of dys-
phagia in early-stage PD suffering from peripheral or central nervous system damage.
The functional capacity of the supramedullary network controlling swallowing is depended
on the in the integrity of dopaminergic neurons in the basal ganglia [20]. A bilateral activation
of putamen and globus pallidus has been exhibited throughout swallowing procedures in a
cohort of healthy controls [21]. Hence, in the context of dopaminergic deficits due to PD a dys-
function in the supramedullary swallowing system would be expected.
The spread of Lewy body pathology in PD, as described by Braak et all, involves several cor-
tical and subcortical areas that elaborate in the regulation of swallowing mechanisms [22].
More specifically, the accumulation of Lewy bodies in areas of the medulla that control swal-
lowing has been associated with severe dysphagia in PD patients. The ascending pattern of
Lewy body pathology in PD initially involves initially dorsal nucleus IX and X and locus coeru-
leus (Stage I-II). These areas are predominantly involved in non-motor symptomatology. Sub-
sequently, spreading of pathology encompasses substantia nigra, mesocortex and neocortex
(Stage III-IV). Thus, motor features of PD become apparent. Following the ascending fashion
of spreading, it would be expected that due to the early involvement of brainstem areas con-
trolling swallowing, relevant symptoms would be evident in the early stages of the disease.
Alas, severe dysphagia is commonly present in advanced PD patients.
This inconsistency could be explained in the context of activation of compensatory mecha-
nisms in cortical areas in early stages of PD. Using whole-head magnetoencephalography, it
has been shown that cortical processing in PD patients without dysphagia harbours a marked
alteration of peak activity regarding lateral regions of premotor, motor, and inferolateral parie-
tal cortex. Furthermore, the activity is activity is reduced in the supplementary motor cortex.
Interestingly, PD patients with dysphagia did not exhibit similar activity. These results are
indicative of an adaptive mechanism with parallel motor networks, aiming to avoid dysphagia.
Dysphagia and presynaptic dopaminergic dysfunction in early drug-naïve Parkinson’s patients
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However, when neurodegeneration exceeds a certain threshold, clinical symptoms of dyspha-
gia might arise.
The absence of instrumental swallowing examination (e.g. Fibreoptic Endoscopic Evalua-
tion of Swallowing and Videofluoroscopic Swallowing Study) as a validated way to assess dys-
phagia is a limitation of our study. However, the use of the clinician-based scale MDS-
UPDRS-II item 2.3 (Chewing and Swallowing) provides a simple tool for clinicians to assess
the presence and progression of dysphagia. Another limitation is depression and anxiety
assessments used in the study are not specific, limiting the generalisation of the findings.
Besides, the presence of apathy could influence the perception of the symptoms.
The use of H&Y scores is robust to assess globally the disease progression in PD, however if
we had MDS-UPDRS III scores for our subjects it could have enhanced precision further.
Finally, the limitation of our study is the correlational approach that does not allow us to per-
form direct attributions and conclude on causality. Therefore, our findings need to be inter-
preted with the appropriate caution.
In conclusion, our results indicate a significant correlation between dysphagia and loss of
striatal dopaminergic function in early drug-naïve PD patients. This specific subgroup of PD
patients harbours a substantial burden of non-motor symptoms, without profound motor
symptomatology.
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